US Compounding Revenue and Competitors

Claim your profile

Conway, AR USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • US Compounding's estimated annual revenue is currently $20.1M per year.(i)
  • US Compounding's estimated revenue per employee is $201,000

Employee Data

  • US Compounding has 100 Employees.(i)
  • US Compounding grew their employee count by -26% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.2M270%N/AN/A
#2
$20.1M100-26%N/AN/A
#3
$78.6M391N/AN/AN/A
#4
$4.3M43105%$50MN/A
#5
$12.3M6139%N/AN/A
#6
$2.1M25-19%N/AN/A
#7
$5M2532%N/AN/A
#8
$2.3M2833%N/AN/A

PCAB accredited compounding-only pharmacy specializing in sterile injectables, bioidentical hormone replacement, the autism spectrum, topical pain therapy, veterinary compounds, and much more. Licensed in over 40 states, US Compounding serves patients, physicians, and surgery centers across the country with the highest-quality compounded medications, helping them solve unique problems in the lives and practices.

keywords:Healthcare,Pharmaceuticals

N/A

Total Funding

100

Number of Employees

$20.1M

Revenue (est)

-26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

US Compounding News

2022-04-20 - Column: Pumped-up dollar compounding global liquidity squeeze

And the U.S. dollar's leading role in global finance and borrowing means the Federal Reserve's rapid conversion to the need for tighter...

2022-04-20 - FDA finishes veterinary drug compounding guidance at last

* The U.S. Food and Drug Administration has issued final guidance on compounding animal drugs from bulk drug substances, a policy nearly 20...

2022-04-17 - US Injectable Compounding Pharmacy Market Size Worth USD ...

US Injectable Compounding Pharmacy Market Size Worth USD 2,153.2 Million by 2028, with Improved Longevity Due to Customized Medicines.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19.1M102-1%N/A
#2
$19.6M1098%N/A
#3
$21.6M1278%N/A
#4
$35.3M13716%N/A
#5
$52.2M146N/AN/A